This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
SUDBURY, Ontario, July 16, 2018 (GLOBE NEWSWIRE) -- Manitou Gold Inc. (TSX-V:MTU) (the “Company” or “Manitou”) is pleased to provide an update on exploration and related activities for its Goudreau area properties.
AGI RIC MTU AMGGF RIC MNTUF ARNGF AGI AR
Investors in Alamos Gold Inc. (AGI - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $2.50 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
AGI LMT AMGGF AGI
GDXJ is a fund of mid-cap gold mining and silver mining shares, which has gained 10% since its intraday bottom of February 9, 2018 while gold bullion has dropped 5%.
GFI.WI EVN YRI KGI.DB NST GLD AGI AUY AMGGF CAHPF GFIOF IAG KL GDXJ KGI KGI.DB.A PAAS GDX 2840 AGI RGRNF NESRF NDAQ RRL GFI NHRNY
TORONTO, July 03, 2018 (GLOBE NEWSWIRE) -- Alamos Gold Inc. (TSX:AGI) (NYSE:AGI) (“Alamos” or the “Company”) plans to release its second quarter 2018 financial results after market close on Wednesday, August 1, 2018. Senior management will host a conference call on Thursday, August 2, 2018 at 11:00 am ET to discuss the results.
AGI AMGGF AGI
IAMGOLD (IAG) is a Canadian gold mining company headquartered in Canada that operates a geographically diverse portfolio of mining assets and potential projects. IAG's producing mines include Essakane, Rosabel, Westwood, and Sadiola gold mines with another gold project under development (Cote gold project). IAG also has five exploration projects which include two joint ventures. During FY 2017, IAG managed to produce ~882 koz (read: thousand ounces) of gold.
ENBBF ABX LUNMF K LUNCF ENB AGI LUN AGI ENB SBGL.WI KGC SBGLF AMGGF EBBNF IAG ABX
VANCOUVER, British Columbia, June 29, 2018 (GLOBE NEWSWIRE) -- ALORO MINING CORP. – (“Aloro” or the “Company”) is pleased to announce that through its Mexican subsidiary, Exploraciones Aloro, S.A. de C.V., has been informed by its environmental consultant that the recently submitted permit application was accepted and a new permit was granted by SEMARNAT on June 27, 2018.
AGI AMGGF AEM AGI
VANCOUVER, B.C., June 26, 2018 (GLOBE NEWSWIRE) -- ALORO MINING CORP. – (“Aloro” or the “Company”) (TSX.V:AORO) (FRANKFURT:4LPP) is pleased to announce that, through its Mexican subsidiary, Exploraciones Aloro, S.A. de C.V., has acquired a further 1,675 hectares, contiguous to the Company’s current 1524 hectares Los Venados claims, bringing Aloro’s current land position in the Mulatos Gold District to 3,199 hectares.
AGI AMGGF AEM AGI
It is indeed a positive development that the trade war between the two biggest world economies United States and China has been put on hold. However, this has taken the luster away from gold, a safe haven for investors in turbulent times.
TOL ABX AU K AGI AGI AULGF KGC AMGGF AGG APR APRLY ABX
VANCOUVER, British Columbia, May 22, 2018 (GLOBE NEWSWIRE) -- Riverside Resources Inc. ("Riverside" or the "Company") (TSX-V:RRI), is pleased to report on the progress of the partner-funded exploration program that is being conducted with Centerra Gold Inc. (“Centerra”) at the Canasta Target on the Glor Project (the “Project”). The Canasta target is located six kilometers to the east of the main Glor concession where Riverside recently drilled with partner Centerra Gold.
AGI CAGDF RRI AMGGF CG AGI RVSDF
Although the markets have their own logic, highly capitalized gold-mining companies seemingly should belong on any “stocks to buy” list. Thanks to rising geopolitical tensions and soaring trading sentiment, many folks seek safe-haven assets. While gold stocks seemingly offer a viable solution, their overall performance has been unusually disappointing.
HMY NCMGF NCM GFI.WI FNV NEM EVN YRI NGDAF BVN NGD RRS AGI SLW KGC BTG AUY AMGGF AEM CAHPF GFIOF IAG GG HGMCF EGO ABX WPM FNV.WT.A NGD ABX RGORF K GOLD AGI SLW GOLD RGLD NCMGY ELD GFI FNV RGL
SUDBURY, Ontario, May 09, 2018 (GLOBE NEWSWIRE) -- Manitou Gold Inc. (TSX-V:MTU) (the “Company” or “Manitou”) is pleased to announce receipt of final reports on the magnetic (“MAG”), induced polarization (“IP”) and soil gas hydrocarbon (“SGH”) surveys completed on its 100% owned “Goudreau Patents.” The Goudreau Patents property consists of four surface and mining rights patents, covering an area of approximately 160 acres and is located less than 2 kms east of the past producing Edwards and Cline mine properties, within the Goudreau-Lochalsh Deformation Zone (the “GLDZ”).
AGI RIC MTU AMGGF RIC MNTUF ARNGF AGI AR
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET